Developer docs
API playgroundTry for free, no card

Search company profiles

QuantX Biosciences

Full company profile

uuid005qvjk

Namestring
QuantX Biosciences
Legal namestring
QuantX Biosciences, Inc.
Websiteurl
quantxbio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

QuantX Biosciences is a privately held, clinical-stage biopharmaceutical company founded in 2022 and headquartered at 103 Carnegie Center, Suite 309, Princeton, New Jersey. The company operates a proprietary computational drug discovery platform that integrates physics-based modeling (accelerated molecular dynamics, free energy perturbation, quantum mechanics) with statistical methods, deep learning, and cheminformatics to design and optimize oral small-molecule drug candidates against clinically validated targets. Its pipeline comprises five disclosed programs: STAT6, IL-17 AA+AF, and TNFα oral small-molecule inhibitors for immunology and inflammatory diseases (atopic dermatitis, asthma, psoriasis, rheumatoid arthritis, hidradenitis suppurativa), and PARG and Pol θ-Helicase inhibitors for solid tumors. Several programs are described as best-in-class or first-in-class oral small molecules with biologic-like efficacy and superior preclinical potency versus competitor small molecules.

The company is pre-commercial and generates no product revenue. Its business model is structured around future licensing deals, co-development arrangements, and potential acquisitions of pipeline assets by larger pharmaceutical partners, with the stated go-to-market motion being enterprise partnering rather than internal commercialization. As of February 2026, QuantX had raised $130 million in total funding, including an oversubscribed $85 million Series B co-led by LAV (Lilly Asia Ventures) and Sanofi Ventures, with participation from Hongshan and existing investors OrbiMed and Creacion Ventures. The company is led by Interim CEO Wei Li, Ph.D. (Founding Partner of Creacion Ventures), Co-founder and President Wayne Tang, Ph.D. (ex-Schrodinger, Merck), Co-founder and CTO Yax Sun, Ph.D. (ex-Amgen, Bristol-Myers Squibb), and CMO Gregory Bell, M.D. (ex-Attralus, KAI Pharmaceuticals, Genentech, Merck), with board representation from OrbiMed, Creacion Ventures, LAV, and Sanofi Ventures.

Short descriptiontext

QuantX Biosciences is a Princeton-based, clinical-stage biotechnology company founded in 2022 that uses a proprietary computational drug discovery platform to design oral small-molecule therapeutics for immunology, inflammation, and oncology indications, with future revenue intended from pharmaceutical licensing and co-development partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational drug discovery, small molecule therapeutics, oral immunology inhibitors, biotechnology drug discovery, medicinal chemistry platform
Industry1 code
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Computational Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pipeline Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue pharmaceutical company focused on developing a pipeline of oral small molecule drug candidates. Revenue will be generated through licensing deals, co-development partnerships with larger pharmaceutical companies, and/or acquisition of pipeline assets. The company is advancing STAT6, IL-17, and TNFα inhibitors toward clinical development.

quantxbio.com
2Discovery Services / Co-development
TypeProfessional Services
Description

Potential revenue from co-development arrangements and strategic partnerships with pharma companies for oral small molecule programs in immunology and inflammation.

quantxbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

QuantX Biosciences operates a proprietary computational drug discovery platform that integrates accelerated molecular dynamics, deep learning–based molecular design, and high-precision free energy perturbation (FEP) and quantum mechanics (QM) simulations to design and optimize oral small molecule drug candidates. The company's pipeline consists of oral small molecule inhibitors targeting clinically validated immunology and inflammation targets (STAT6, IL-17 AA+AF, TNFα) plus oncology targets (PARG, Pol θ-Helicase), developed for in-licensing, co-development, or acquisition by larger pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • STAT6 lead candidate is a highly potent small molecule that selectively blocks STAT6 activation, combining biologic-like efficacy with oral small molecule therapy convenience.
+3 more records
Product overview1 text field

QuantX Biosciences operates a computationally-driven drug discovery platform that integrates physics-based modeling, statistical methods, and computational chemistry to design and optimize oral small molecule therapeutics. The company's pipeline consists of multiple oral small molecule inhibitor programs targeting clinically validated immunology and inflammation targets: STAT6 inhibitors (for asthma, atopic dermatitis), IL-17 AA+AF inhibitors (for psoriasis, hidradenitis suppurativa), TNFα inhibitors (for rheumatoid arthritis), plus PARG and Pol θ-Helicase inhibitors for oncology. The computational platform powers iterative drug discovery from target validation through lead optimization.

Product and service5 records
1STAT6 Oral Small Molecule Inhibitor
CategoryCore Product - Immunology/Inflammation Pipeline Program
Description

A highly potent, selective oral small molecule inhibitor targeting STAT6, a key transcription factor driving Type 2 inflammation. Being developed for atopic dermatitis, asthma, and other Type 2 inflammatory diseases, combining biologic-like efficacy with oral small molecule convenience. Intended for in-licensing or co-development by pharmaceutical partners.

2IL-17 AA + AF Oral Small Molecule Inhibitor
CategoryCore Product - Immunology/Inflammation Pipeline Program
Description

A dual oral small molecule inhibitor targeting IL-17AA and IL-17AF for the treatment of psoriasis and broader autoimmune applications. In vivo lead compounds show superior potency versus competitor small molecules and demonstrate significant suppression of arthritis in rat CIA models. Intended for in-licensing or co-development by pharmaceutical partners.

3TNFα Oral Small Molecule Inhibitor
CategoryCore Product - Immunology/Inflammation Pipeline Program
Description

An oral small molecule TNFα inhibitor in development for rheumatoid arthritis and broader autoimmune applications. Demonstrates best-in-class small molecule profile with good tolerability in preclinical studies, offering advantages over biologics including ease of administration and reduced immunogenicity. Intended for in-licensing or co-development by pharmaceutical partners.

4PARG Inhibitor
CategoryCore Product - Oncology Pipeline Program
Description

A small molecule inhibitor targeting PARG (poly ADP-ribose glycohydrolase) being developed for the treatment of solid tumors. Intended for in-licensing or co-development by pharmaceutical partners.

5Pol θ-Helicase Inhibitor
CategoryCore Product - Oncology Pipeline Program
Description

A small molecule inhibitor targeting Pol θ (DNA polymerase theta) helicase domain being developed for the treatment of solid tumors. Intended for in-licensing or co-development by pharmaceutical partners.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Exscientia pioneered AI-designed small molecule drug discovery with multiple pharma partnerships and clinical-stage assets, including immunology indications. Comparable as a computational-first discovery company pursuing licensing and partnered development.

TypeDirect peer
Description

InSilico Medicine operates an AI-driven drug discovery platform (PandaOmics, Chemistry42) and has advanced multiple small molecule programs into clinical development, including immunology and oncology — comparable to QuantX's pipeline mix and platform-driven approach.

TypeDirect peer
Description

Schrödinger operates a physics-based computational drug discovery platform (FEP+, molecular dynamics) and runs internal and partnered programs — QuantX co-founder Wayne Tang previously led drug discovery at Schrödinger, making the business model, technology stack, and target classes highly comparable.

TypeDirect peer
Description

Insitro uses ML combined with high-throughput biology to discover and develop small molecule therapeutics. Similar positioning as a privately-held, well-funded platform biotech pursuing partnered and internal programs.

TypeDirect peer
Description

Recursion combines high-throughput biology with AI/ML for small molecule discovery across multiple therapeutic areas, including immunology and oncology. Comparable in applying computational methods to industrialize pipeline generation and target prioritization.

TypeDirect peer
Description

XtalPi combines physics-based modeling, quantum mechanics, and AI for small molecule and crystal form prediction, with active pharmaceutical partnerships. Comparable in technology stack (FEP, QM, generative chemistry) and in serving both internal and partnered programs.

TypeEmerging player
Description

Atomwise uses AI for small molecule hit identification and lead optimization across multiple therapeutic areas, with partnered programs in immunology and oncology. Comparable as an early-stage AI-discovery platform, though smaller in pipeline depth.

8Isomorphic Labs
TypeDirect peer
Description

Isomorphic Labs (Alphabet) applies deep learning and physics-based modeling to drug discovery with a focus on small molecules against validated targets. Comparable in applying state-of-the-art computational methods to industrialize drug design.

TypeEmerging player
Description

BenevolentAI applies AI to drug discovery across inflammation, immunology, and rare diseases. Comparable in using computational methods to identify novel targets and indications, though focused more on target identification than on advanced lead optimization.

TypeEmerging player
Description

Verge Genomics uses AI/ML on human multi-omics data for drug discovery, primarily in neuroscience and rare diseases. Comparable as a platform biotech using computational methods to de-risk target selection and pipeline generation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QuantX Biosciences

Computational Drug Discoveryquantxbio.com

QuantX Biosciences is a Princeton-based, clinical-stage biotechnology company founded in 2022 that uses a proprietary computational drug discovery platform to design oral small-molecule therapeutics for immunology, inflammation, and oncology indications, with future revenue intended from pharmaceutical licensing and co-development partnerships.

What QuantX Biosciences does

QuantX Biosciences is a privately held, clinical-stage biopharmaceutical company founded in 2022 and headquartered at 103 Carnegie Center, Suite 309, Princeton, New Jersey. The company operates a proprietary computational drug discovery platform that integrates physics-based modeling (accelerated molecular dynamics, free energy perturbation, quantum mechanics) with statistical methods, deep learning, and cheminformatics to design and optimize oral small-molecule drug candidates against clinically validated targets. Its pipeline comprises five disclosed programs: STAT6, IL-17 AA+AF, and TNFα oral small-molecule inhibitors for immunology and inflammatory diseases (atopic dermatitis, asthma, psoriasis, rheumatoid arthritis, hidradenitis suppurativa), and PARG and Pol θ-Helicase inhibitors for solid tumors. Several programs are described as best-in-class or first-in-class oral small molecules with biologic-like efficacy and superior preclinical potency versus competitor small molecules.

The company is pre-commercial and generates no product revenue. Its business model is structured around future licensing deals, co-development arrangements, and potential acquisitions of pipeline assets by larger pharmaceutical partners, with the stated go-to-market motion being enterprise partnering rather than internal commercialization. As of February 2026, QuantX had raised $130 million in total funding, including an oversubscribed $85 million Series B co-led by LAV (Lilly Asia Ventures) and Sanofi Ventures, with participation from Hongshan and existing investors OrbiMed and Creacion Ventures. The company is led by Interim CEO Wei Li, Ph.D. (Founding Partner of Creacion Ventures), Co-founder and President Wayne Tang, Ph.D. (ex-Schrodinger, Merck), Co-founder and CTO Yax Sun, Ph.D. (ex-Amgen, Bristol-Myers Squibb), and CMO Gregory Bell, M.D. (ex-Attralus, KAI Pharmaceuticals, Genentech, Merck), with board representation from OrbiMed, Creacion Ventures, LAV, and Sanofi Ventures.

QuantX Biosciences firmographics

Firmographics
Name
QuantX Biosciences
Legal name
QuantX Biosciences, Inc.
Website
https://quantxbio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
QuantX Biosciences is a Princeton-based, clinical-stage biotechnology company founded in 2022 that uses a proprietary computational drug discovery platform to design oral small-molecule therapeutics for immunology, inflammation, and oncology indications, with future revenue intended from pharmaceutical licensing and co-development partnerships.
Ownership category
akta.pro rank

QuantX Biosciences industry classification

Industry
Product category
Computational Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Computational drug discovery
  • Small molecule therapeutics
  • Oral immunology inhibitors
  • Biotechnology drug discovery
  • Medicinal chemistry platform

Where QuantX Biosciences is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

QuantX Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pipeline Development and Licensing: Pre-revenue pharmaceutical company focused on developing a pipeline of oral small molecule drug candidates. Revenue will be generated through licensing deals, co-development partnerships with larger pharmaceutical companies, and/or acquisition of pipeline assets. The company is advancing STAT6, IL-17, and TNFα inhibitors toward clinical development.
  2. Discovery Services / Co-development: Potential revenue from co-development arrangements and strategic partnerships with pharma companies for oral small molecule programs in immunology and inflammation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

QuantX Biosciences product offering

Product offering

Core offering

QuantX Biosciences operates a proprietary computational drug discovery platform that integrates accelerated molecular dynamics, deep learning–based molecular design, and high-precision free energy perturbation (FEP) and quantum mechanics (QM) simulations to design and optimize oral small molecule drug candidates. The company's pipeline consists of oral small molecule inhibitors targeting clinically validated immunology and inflammation targets (STAT6, IL-17 AA+AF, TNFα) plus oncology targets (PARG, Pol θ-Helicase), developed for in-licensing, co-development, or acquisition by larger pharmaceutical partners.

Product overview

QuantX Biosciences operates a computationally-driven drug discovery platform that integrates physics-based modeling, statistical methods, and computational chemistry to design and optimize oral small molecule therapeutics. The company's pipeline consists of multiple oral small molecule inhibitor programs targeting clinically validated immunology and inflammation targets: STAT6 inhibitors (for asthma, atopic dermatitis), IL-17 AA+AF inhibitors (for psoriasis, hidradenitis suppurativa), TNFα inhibitors (for rheumatoid arthritis), plus PARG and Pol θ-Helicase inhibitors for oncology. The computational platform powers iterative drug discovery from target validation through lead optimization.

Differentiator

Problem solved

Functional benefit

Products and services

  • STAT6 Oral Small Molecule Inhibitor A highly potent, selective oral small molecule inhibitor targeting STAT6, a key transcription factor driving Type 2 inflammation. Being developed for atopic dermatitis, asthma, and other Type 2 inflammatory diseases, combining biologic-like efficacy with oral small molecule convenience. Intended for in-licensing or co-development by pharmaceutical partners.
  • IL-17 AA + AF Oral Small Molecule Inhibitor A dual oral small molecule inhibitor targeting IL-17AA and IL-17AF for the treatment of psoriasis and broader autoimmune applications. In vivo lead compounds show superior potency versus competitor small molecules and demonstrate significant suppression of arthritis in rat CIA models. Intended for in-licensing or co-development by pharmaceutical partners.
  • TNFα Oral Small Molecule Inhibitor An oral small molecule TNFα inhibitor in development for rheumatoid arthritis and broader autoimmune applications. Demonstrates best-in-class small molecule profile with good tolerability in preclinical studies, offering advantages over biologics including ease of administration and reduced immunogenicity. Intended for in-licensing or co-development by pharmaceutical partners.
  • PARG Inhibitor A small molecule inhibitor targeting PARG (poly ADP-ribose glycohydrolase) being developed for the treatment of solid tumors. Intended for in-licensing or co-development by pharmaceutical partners.
  • Pol θ-Helicase Inhibitor A small molecule inhibitor targeting Pol θ (DNA polymerase theta) helicase domain being developed for the treatment of solid tumors. Intended for in-licensing or co-development by pharmaceutical partners.

Quantifiable outcome

  • STAT6 lead candidate is a highly potent small molecule that selectively blocks STAT6 activation, combining biologic-like efficacy with oral small molecule therapy convenience.
  • +3 more outcomes

Companies that use QuantX Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

QuantX Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

QuantX Biosciences partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

QuantX Biosciences competitors and assessment

Company assessment

Direct peers

  • Exscientia: Exscientia pioneered AI-designed small molecule drug discovery with multiple pharma partnerships and clinical-stage assets, including immunology indications. Comparable as a computational-first discovery company pursuing licensing and partnered development.
  • InSilico Medicine: InSilico Medicine operates an AI-driven drug discovery platform (PandaOmics, Chemistry42) and has advanced multiple small molecule programs into clinical development, including immunology and oncology — comparable to QuantX's pipeline mix and platform-driven approach.
  • Schrödinger: Schrödinger operates a physics-based computational drug discovery platform (FEP+, molecular dynamics) and runs internal and partnered programs — QuantX co-founder Wayne Tang previously led drug discovery at Schrödinger, making the business model, technology stack, and target classes highly comparable.
  • Insitro: Insitro uses ML combined with high-throughput biology to discover and develop small molecule therapeutics. Similar positioning as a privately-held, well-funded platform biotech pursuing partnered and internal programs.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML for small molecule discovery across multiple therapeutic areas, including immunology and oncology. Comparable in applying computational methods to industrialize pipeline generation and target prioritization.
  • XtalPi: XtalPi combines physics-based modeling, quantum mechanics, and AI for small molecule and crystal form prediction, with active pharmaceutical partnerships. Comparable in technology stack (FEP, QM, generative chemistry) and in serving both internal and partnered programs.
  • Isomorphic Labs: Isomorphic Labs (Alphabet) applies deep learning and physics-based modeling to drug discovery with a focus on small molecules against validated targets. Comparable in applying state-of-the-art computational methods to industrialize drug design.

Emerging players

  • Atomwise: Atomwise uses AI for small molecule hit identification and lead optimization across multiple therapeutic areas, with partnered programs in immunology and oncology. Comparable as an early-stage AI-discovery platform, though smaller in pipeline depth.
  • BenevolentAI: BenevolentAI applies AI to drug discovery across inflammation, immunology, and rare diseases. Comparable in using computational methods to identify novel targets and indications, though focused more on target identification than on advanced lead optimization.
  • Verge Genomics: Verge Genomics uses AI/ML on human multi-omics data for drug discovery, primarily in neuroscience and rare diseases. Comparable as a platform biotech using computational methods to de-risk target selection and pipeline generation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

QuantX Biosciences social profiles

Digital presence

QuantX Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QuantX Biosciences leadership team

Management profile

Number of profiles

Profiles7 records

QuantX Biosciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QuantX Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QuantX Biosciences

What does QuantX Biosciences do?

QuantX Biosciences operates a proprietary computational drug discovery platform that integrates accelerated molecular dynamics, deep learning–based molecular design, and high-precision free energy perturbation (FEP) and quantum mechanics (QM) simulations to design and optimize oral small molecule drug candidates. The company's pipeline consists of oral small molecule inhibitors targeting clinically validated immunology and inflammation targets (STAT6, IL-17 AA+AF, TNFα) plus oncology targets (PARG, Pol θ-Helicase), developed for in-licensing, co-development, or acquisition by larger pharmaceutical partners.

Is QuantX Biosciences a public or private company?

QuantX Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was QuantX Biosciences founded?

QuantX Biosciences was founded in 2022. It employs 11 to 50 people.

Where is QuantX Biosciences based?

QuantX Biosciences is headquartered in Princeton, United States, in the North America region.

How does QuantX Biosciences make money?

Two revenue lines are on record. Pipeline Development and Licensing is the primary driver. The others are discovery Services / Co-development.

Who are QuantX Biosciences's main competitors?

Direct peers on record are Exscientia, InSilico Medicine, Schrödinger, Insitro, Recursion Pharmaceuticals, XtalPi and Isomorphic Labs. Emerging players are Atomwise, BenevolentAI and Verge Genomics.

Does QuantX Biosciences have an API?

No public API is recorded for QuantX Biosciences.

What industry is QuantX Biosciences in?

QuantX Biosciences's product category is Computational Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumILiAD bags $115m for pertussis vaccine, and other financingsILiAD Biotechnologies raised $115 million in a Series B financing led by RA Capital Management to advance its BPZE1 live, attenuated pertussis (whooping cough) vaccine candidate, which is delivered intranasally and licensed from Institut Pasteur de Lille and Inserm in France. The funding will support a pivotal human challenge trial starting later this year with results expected in 2027, as whooping cough cases rise in Europe and the US due to declining childhood vaccination rates. The article also covers four additional biotech financings: QuantX Biosciences ($85M Series B for inflammatory disease drugs), Aerska ($39M Series A for CNS RNA therapeutics), Galux ($29M for AI-designed protein therapeutics), and Pandorum Technologies ($18M Series B for exosome-based ocular therapies).QuantxbioQuantX Biosciences Closes Oversubscribed $85M Series B FinancingQuantX Biosciences has closed an $85 million oversubscribed Series B financing round co-led by Sanofi Ventures and LAV, with participation from Hongshan and existing investors including OrbiMed and Creacion Ventures. The proceeds will fund clinical development of the company's STAT6 and IL-17 oral small molecule inhibitors in immunology and inflammation, as well as continued discovery efforts. The Princeton, New Jersey-based company, co-founded in 2022, has now raised $130 million total to date.Venture Capital Access OnlineQuantX Biosciences Closes Oversubscribed $85M Series B FinancingQuantX Biosciences announced the close of an $85 million Series B financing round co-led by LAV and Sanofi Ventures, with participation from Hongshan and existing investors. The proceeds will support clinical development of the company's STAT6 and IL-17 oral small molecule inhibitors, as well as continued discovery efforts in immunology and inflammation. The company, co-founded in 2022 and previously incubated by OrbiMed and Creacion Ventures, has now raised $130 million to date.BioSpaceQuantX Biosciences Closes Oversubscribed $85M Series B FinancingQuantX Biosciences announced the close of an oversubscribed $85 million Series B financing round co-led by LAV and Sanofi Ventures, with participation from Hongshan and existing investors including OrbiMed. The proceeds will support clinical development of its STAT6 and IL-17 oral small molecule inhibitors, as well as continued discovery efforts in immunology and inflammation. The company, co-founded in 2022 and previously incubated by OrbiMed and Creacion Ventures, has now raised $130 million to date.